Fochon Pharmaceuticals, Ltd.

Shanghai Fochon Pharmaceutical Co., Ltd.

Chongqing Fochon Pharmaceutical Co., Ltd.

Other

Chinese Academy of Sciences

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Fochon Biosciences, Ltd.

Fochon Pharmaceutical Co., Ltd.

Rui Tan

Weibo Wang

Xingdong Zhao

Haohan Tan

Xianlong Wang

Zuwen Zhou

Yanxin Liu

Jing Sun

Zhifang Chen

Zhifu Li

Yue Rong

Lijun Yang

Tongshuang Li

Lihua Jiang

Weipeng Zhang

Qihong Liu

Hongbin Liu

Huajie Zhang

Min Lin

Ling Chen

Chengxi He

Zongyao Zou

Bin Liu

Kai Ran

Li Linghu

Shu Lin

Yunling Wang

Jiemin Fu

Chuiliang Yu

Jian Ding

Meiyu Geng

Linghua Meng

Tao Cheng

Guohua Wang

Yuwei Gao

Hong Fu

Guoying Bai

Ran Wang

A deep learning-based examination and diagnosis assistance system and apparatus for early digestive tract cancer comprising a feature extraction network, an image classification model, an endoscope classifier, and an early cancer recognition model. The feature extraction network is used for performing initial feature extraction on endoscope images based on a neural network model; the image classification model is used for performing extraction on the initial features to acquire image classification features; the endoscope classifier is used for performing feature extraction on the initial features to acquire endoscope classification features and classify gastroscope/colonoscope images; the early cancer recognition model is used for splicing the initial features, the endoscope classification features, and the image classification features to acquire the probability of early cancer lesions in white light images, electronic dye images or chemical dye images of a corresponding site or acquire a flushing prompt or position recognition prompt for the corresponding site.

Deep learning based auxiliary diagnosis system for early gastrointestinal cancer and inspection device

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Apoptosis-inducing agents

Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Macrocyclic compounds as TRK kinases inhibitors

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds thereof, and use of these compounds in preparing drugs for inhibiting ROCK. 

Deuterated compounds as rock inhibitors

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase

Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders. 

Compounds as BLC-2-selective apoptosis-inducing agents

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Indolizine derivatives, composition and methods of use

Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.

Certain protein kinase inhibitors

Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors

Provided are certain CDK4/6 inhibitors with the structure of formula (I), pharmaceutical compositions thereof, and methods of use therefor. The compounds are of the class of pyrimidin-2 amine derivatives, useful for the treatment of hyper-proliferative diseases. 

Certain protein kinase inhibitor

Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Growing community of inventors

Chongqing, China

Rui Tan